Exp Clin Endocrinol Diabetes 2019; 127(01): 62-67
DOI: 10.1055/a-0630-0318
Article
© Georg Thieme Verlag KG Stuttgart · New York

Expenditures Of Metabolic Diseases – An Estimation on National Health Care Expenditures of Diabetes and Obesity, Hungary 2013

Gabriella Iski
1   Faculty of Public health, Department of Family and Occupational Medicine, University of Debrecen, Debrecen, Hungary
,
Sarolta E. Rurik
2   Independent macroeconomic adviser
,
Imre Rurik
1   Faculty of Public health, Department of Family and Occupational Medicine, University of Debrecen, Debrecen, Hungary
› Author Affiliations
Further Information

Publication History

received 18 November 2017
revised 18 November 2017

accepted 07 May 2018

Publication Date:
02 July 2018 (online)

Preview

Abstract

Background Obesity could be considered as the main consequence of unhealthy nutrition, responsible for many pathological alterations in human. Obese patients usually need more health care services. The aim of the study was to estimate the financial expenditures of health care provisions in Hungary, related to obesity and diabetes, as its main pathological consequence.

Methods Data of the Hungarian National Health Insurance Fund (NHIF) were collected for 2013, regarding finances of secondary care, hospital services, reimbursement for medications and healing aids of diabetic patients together with selected morbidities linked to obesity, based on the codes of the International Classification of Diseases (ICD) and calculated their population prevalence on the population-attributable fraction (PAF).

Results Financial data regarding diabetes care resulted in a 40,311 Million HUF (129 Million EUR) national fund expenses, beside a 7,173 Million HUF (23 Million EUR) contribution from patients. Estimated total health care expenditures related to obesity were 58,986 Million HUF (188 Million EUR) and the financial contribution of patients was calculated as 25,316 Million HUF (81 Million EUR). These data represent a 5.2% and 9.3% of the whole national health services, 16% and 30% of the whole drug-reimbursement budgets, respectively.

Conclusions Although expenditures for some obesity related pathologies analyzed in this paper represent 0.28% of the national GDP, considering other morbidities and other patient’s expenses, the real ratio could be between 0.5–1%. The increasing number of overweight and obese persons requires more focus in public health, higher awareness in the society and more governmental support.